Cargando…

Targeting STAT6 in PMBL

Detalles Bibliográficos
Autores principales:	Leroy, Karen, Pujals, Anais, Pelletier, Laura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202119/ https://www.ncbi.nlm.nih.gov/pubmed/25277174

Ejemplares similares

Double-punching PMBL
por: Lennerz, Jochen K.
Publicado: (2014)

Targeting the intratumor heterogeneity in PMBL
por: Ritz, Olga, et al.
Publicado: (2014)

STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL)
por: Ritz, Olga, et al.
Publicado: (2013)

Transformation of FL into DLBCL with a PMBL gene expression signature
por: Loveday, Tristan, et al.
Publicado: (2022)

Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL
por: Chu, Yaya, et al.
Publicado: (2020)

Targeting STAT3 and STAT5 in Cancer
por: de Araujo, Elvin D., et al.
Publicado: (2020)

Targeting BCL6 and STAT3 in triple negative breast cancer: the one-two punch?
por: Walker, Sarah R., et al.
Publicado: (2015)

Targeting the STAT5 pathway in Ph+ acute lymphoblastic leukemia
por: Minieri, Valentina, et al.
Publicado: (2018)

STAT5b in LGL leukemia – a novel therapeutic target?
por: Rajala, Hanna L. M., et al.
Publicado: (2013)

Role of STAT3 dependent SOX2 and CD24 expression in melanoma cell adaptive resistance towards targeted therapies
por: Hüser, Laura, et al.
Publicado: (2019)

Isolated 5′ Signals Are an Atypical Pattern To Be Considered as Positive for ALK Rearrangement: A Brief Report of Three Cases and Review of the Literature()
por: Guyard, Alice, et al.
Publicado: (2019)

Inflammation, cytokines, the IL-17/IL-6/STAT3/NF-κB axis, and tumorigenesis
por: Chen, Xiao-Wu, et al.
Publicado: (2015)

JAK-STAT in lymphoproliferative disorders
por: Rabadan, Raul, et al.
Publicado: (2015)

JAK-STAT Signalling Pathway in Cancer
por: Brooks, Andrew J., et al.
Publicado: (2020)

The STATus of STAT3 in Lung Cell Senescence?
por: Adnot, Serge, et al.
Publicado: (2019)

Special Issue “Role of STAT3 in Oncogenesis”
por: Ahn, Kwang Seok
Publicado: (2022)

The BCL‐2 family protein inhibitor ABT‐737 as an additional tool for the treatment of EBV‐associated post‐transplant lymphoproliferative disorders
por: Robert, Aude, et al.
Publicado: (2020)

Drugging the “undruggable” DNA-binding domain of STAT3
por: Zhang, Jian-Ting, et al.
Publicado: (2016)

Surprise, surprise: STAT5 is not enough to stop the steroids
por: Fernandes, Marta B., et al.
Publicado: (2022)

Critical Care Delivery in India: Stats, State(s) and Strategies
por: Ramakrishnan, Adarsh, et al.
Publicado: (2023)

Expression of JAK3, STAT2, STAT4, and STAT6 in pemphigus vulgaris
por: Juczynska, K., et al.
Publicado: (2020)

The Endothelium Is in Shock and IFN-α/STAT1 Signaling Is to Blame
por: Farkas, Laszlo
Publicado: (2021)

Anti-STAT6 CTL activity in Stat6(−/−) mice: A cautionary tale
por: Kaplan, Mark H., et al.
Publicado: (2013)

STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer
por: Attili, Ilaria, et al.
Publicado: (2018)

STAT2-directed pathogen responses
por: Bluyssen, Hans
Publicado: (2015)

STAT6 and lung inflammation
por: Walford, Hannah H, et al.
Publicado: (2013)

STAT3 and mTOR: co-operating to drive HIF and angiogenesis
por: Dodd, Kayleigh M., et al.
Publicado: (2015)

Epithelial STAT3: A New Twist in Inducible Antimicrobial Resistance
por: Le, John, et al.
Publicado: (2023)

Grail controls Th2 cell development by targeting STAT6 for degradation
por: Sahoo, Anupama, et al.
Publicado: (2014)

IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma
por: Xu, Junnv, et al.
Publicado: (2021)

PARP14 is a novel target in STAT6 mutant follicular lymphoma
por: Mentz, Michael, et al.
Publicado: (2022)

Multivalent effect of peptide functionalized polymeric nanoparticles towards selective prostate cancer targeting
por: Murar, Madhura, et al.
Publicado: (2023)

STAT3 as a biologically relevant target in H3K27M-mutant diffuse midline glioma
por: Anderson, Jacob B., et al.
Publicado: (2023)

Direct Targeting Options for STAT3 and STAT5 in Cancer
por: Orlova, Anna, et al.
Publicado: (2019)

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–6
por: Vanden Eynde, Jean Jacques, et al.
Publicado: (2019)

Bound Together: RNA Binding Protein Quaking, STAT3, and Pulmonary Vascular Remodeling
por: Frump, Andrea L., et al.
Publicado: (2023)

Characterization of STAT6 Target Genes in Human B Cells and Lung Epithelial Cells
por: Kanai, Akinori, et al.
Publicado: (2011)

On the role of STAT1 and STAT6 ADP-ribosylation in the regulation of macrophage activation
por: Begitt, Andreas, et al.
Publicado: (2018)

Dual STAT-3 and IL-6R inhibition with stattic and tocilizumab decreases migration, invasion and proliferation of prostate cancer cells by targeting the IL-6/IL-6R/STAT-3 axis
por: Méndez-Clemente, Anibal, et al.
Publicado: (2022)

UDP-α-D-glucose 6-dehydrogenase: a promising target for glioblastoma
por: Goodwin, C. Rory, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_318el0urk4omqpjdsuf7g2cfq7